2-(o-tolyldisulfaneyl)pyridine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(o-tolyldisulfaneyl)pyridine
• 英文别名: [2]pyridyl-o-tolyl disulfide；[2]Pyridyl-o-tolyl-disulfid；(2-Pyridyldithio)-toluene；2-[(2-methylphenyl)disulfanyl]pyridine
• 化学式: C₁₂H₁₁NS₂
• 分子量: 233.358
• InChiKey: YRJADZYFKNSORZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  63.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-巯基吡啶 在 甲醇 、 sodium hydroxide 作用下， 生成 2-(o-tolyldisulfaneyl)pyridine
  参考文献：
  名称：

  Runge et al., Journal fur praktische Chemie (Leipzig 1954), 1959, vol. <4> 8, p. 44,46, 48, 50

  摘要：

  DOI：

文献信息

• Photocleavable isotope-coded affinity tags
  申请人：Olejnik Jerzy

  公开号：US20050085630A1

  公开（公告）日：2005-04-21

  This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as proteins and protein fragments from biological samples from in vivo and in vitro sources. Agents comprise a detectable group bound to a photoreactive group. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals.

  本发明涉及可以用于检测和分离来自复杂混合物（如来自体内和体外源的生物样本中的蛋白质和蛋白质片段）的靶组分的试剂和结合物。试剂包括结合到光反应基团的可检测基团。结合物包括通过共价键结合到底物的试剂，这些共价键可以通过电磁辐射的施加而选择性地断裂。标记有可检测分子的目标物质可以很容易地从异源混合物中识别和分离出来。将结合物暴露于辐射会释放出目标物质以功能形式完全不变。使用光解分子前体作为结合物，标记可以被结合到大分子中，新生大分子被分离并标记完全去除。该发明还涉及使用这些结合物分离出的目标物质，这些目标物质可能作为药用剂或可用于给人类和其他哺乳动物的组合物。
• Disulfide metathesis <i>via</i> sulfur⋯iodine interaction and photoswitchability
  作者：Ashis Mathuri、Milan Pramanik、Amarchand Parida、Prasenjit Mal

  DOI：10.1039/d1ob01581h

  日期：——

  The idea of constitutional dynamic chemistry (CDC) and dynamic combinatorial chemistry (DCC) is widespread in the literature using the chemistry of disulfides. The synthesis of unsymmetrical diaryl disulfides is challenging due to the presence of a weak S–S bond. We report herein the synthesis of unsymmetrical diaryl disulfides from two symmetrical disulfides via a cross-metathesis reaction which was

  组成动态化学 (CDC) 和动态组合化学 (DCC) 的想法在使用二硫化物化学的文献中很普遍。由于存在弱 S-S 键，不对称二芳基二硫化物的合成具有挑战性。我们在此报告了通过由弱硫⋯碘 (S⋯I) 相互作用控制的交叉复分解反应从两个对称二硫化物合成不对称二芳基二硫化物。在N-碘代琥珀酰亚胺 (NIS)存在下，不对称二硫化物在乙腈溶液中是稳定的，并且发现在可见光照射下可可逆地光转换为对称二硫化物。
• Compositions and methods for targeted delivery of immune response modifiers
  申请人：Alkan Sefik

  公开号：US20060142202A1

  公开（公告）日：2006-06-29

  The present invention provides immunomodulatory compositions include an immune response modifier moiety coupled to a targeting moiety. In another aspect, the invention provides methods of providing targeted delivery of an IRM, generating a localized immune response, and treating a condition in a subject. Generally, the methods include administering to the subject an immunomodulatory composition that includes an immune response modifier moiety coupled to a targeting moiety that recognizes a delivery target.

  本发明提供的免疫调节组合物包括将免疫反应修饰物与靶向修饰物耦合在一起。在另一个方面，本发明提供提供定向输送IRM、生成局部免疫反应和治疗受体的方法。通常，这些方法包括向受体注射免疫调节组合物，该组合物包括将免疫反应修饰物与能识别输送目标的靶向修饰物耦合在一起。
• Antibodies containing therapeutic TPO/EPO mimetic peptides
  申请人：Alexion Pharmaceuticals, Inc.

  公开号：EP2752427A1

  公开（公告）日：2014-07-09

  The present disclosure features therapeutic antibodies (e.g., TPO mimetic antibodies) and therapeutically-active fragments thereof as well as methods for preparing and using the antibodies and fragments. For example, the therapeutic antibodies and their fragments are useful in a variety of diagnostic and/or therapeutic applications such as methods for increasing platelet levels in a subject.

  本公开的内容包括治疗性抗体（例如，TPO模拟抗体）及其治疗活性片段，以及制备和使用抗体及片段的方法。例如，治疗性抗体及其片段可用于各种诊断和/或治疗应用，如提高受试者血小板水平的方法。
• METHOD FOR PREPARING ANTIBODY-DRUG CONJUGATE
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：EP3603663A1

  公开（公告）日：2020-02-05

  A method for preparing an antibody-drug conjugate (ADC). In particular, the method mainly utilizes a combination of antibody biomolecules and an ion exchange carrier through electrostatic interaction to realize solid phase preparation of an ADC drug. Elution conditions are optimized, to control a drug-to-antibody coupling ratio (DAR) and separate a polymer-coupled drug, reduce the amount of a drug used in a coupling reaction, and enhance the targeted therapeutic effect of an ADC drug. The preparation method features fewer steps, simple operation, and programmable control, facilitating industrial scale-up production, and also realizing zero retention of reducing agents and organic solvents in the preparation process, significantly improving drug safety and reducing production costs.

  一种制备抗体药物共轭物（ADC）的方法。具体而言，该方法主要利用抗体生物大分子与离子交换载体通过静电作用结合，实现 ADC 药物的固相制备。通过优化洗脱条件，控制药物与抗体的偶联比（DAR），分离聚合物偶联药物，减少偶联反应中的药物用量，提高ADC药物的靶向治疗效果。该制备方法具有步骤少、操作简单、可编程控制等特点，有利于工业化放大生产，同时实现了还原剂和有机溶剂在制备过程中的零残留，大大提高了药物的安全性，降低了生产成本。